Google Scholar Citations of our work in Google Scholar


 Leroy, B., Ballinger, M. L., Baran-Marszak, F., Bond, G. L., Braithwaite, A., Concin, N., Donehower, L. A., El-Deiry, W. S., Fenaux, P., Gaidano, G., Langerød, A., Hellstrom-Lindberg, E., Iggo, R., Lehmann-Che, J., Mai, P. L., Malkin, D., Moll, U. M., Myers, J. N., Nichols, K. E., Pospisilova, S., Ashton-Prolla, P., Rossi, D., Savage, S. A., Strong, L. C., Tonin, P. N., Zeillinger, R., Zenz, T., Fraumeni, J. F., Taschner, P. E., Hainaut, P., and Soussi, T. (2017). Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res 6, 1250-1260. LINK (open access)

Soussi, T., and Kroemer, G. (2016). TP53 and 53BP1 Reunited. Trends Cell Biol in press


Soussi, T., Taschner, P. E., and Samuels, Y. (2017). Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications. Hum Mutat 38, 339-342.

Lazarian G, Tausch E, Eclache V, Sebaa A, Bianchi V, Letestu R, Collon JF, Lefebvre V, Gardano L, Varin-Blank N, Soussi T, Stilgenbauer S, Cymbalista F, Baran-Marszak F (2016) TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. Int J Cancer, 139: 1759–1763; PDF LINK

Lodé L, Cymbalista F, Soussi T (2016) Genetic profiling of CLL: a 'TP53 addict' perspective. Cell Death Dis, 7: e2042; PDF; LINK


 Soussi T, Wiman KG (2015) TP53: an oncogene in disguise. Cell Death Differ, 22: 1239–1249; PDF; LINK


Soussi T (2014) The TP53 Gene Network in a Post-Genomic Era. Hum Mutat, 35: 641–642; PDF; LINK

Soussi T (2014) Locus-Specific Databases in Cancer: What Future in a Post-Genomic Era? The TP53 LSDB Paradigm. Hum Mutat, 35: 643–653; PDF; LINK

Leroy B, Anderson M & Soussi T (2014) TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. Hum Mutat, 35: 672–688; PDF; LINK

Leroy B, Girard L, Hollestelle A, Minna JD, Gazdar AF & Soussi T (2014) Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment. Hum Mutat, 35: 756–765; PDF; LINK

Soussi T, Leroy B & Taschner PE (2014) Recommendations for Analyzing and Reporting TP53 Gene Variants in the High-Throughput Sequencing Era. Hum Mutat, 35: 766–778; PDF; LINK


Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G & Soussi T (2013) The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res, 41: D962–D969 ; PDFLINK


Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B, Sundstrom M, Micke P, Botling J & Soussi T (2012) Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A, 109: 9551–9556  PDFLINK


Soussi T (2011) TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. Adv Cancer Res, 110: 107–139  PDFLINK

Soussi T (2011) Advances in carcinogenesis: A historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. Biochim Biophys Acta, 1816: 199–208  PDFLINK


Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T, Helfrich H, Heuberger M, Hoth P, Fuge M, Denzel T, Habe S, Malcikova J, Kuglik P, Truong S, Patten N, Wu L, Oscier D, Ibbotson R, Gardiner A, Tracy I, Lin K, Pettitt A, Pospisilova S, Mayer J, Hallek M, Dohner H & Stilgenbauer S (2010) TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia, 24: 2072–2079  PDFLINK

Soussi T, Hamroun D, Hjortsberg L, Rubio-Nevado JM, Fournier JL & Beroud C (2010) MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer. Hum Mutat, 31: 1020–1025  PDFLINK

Lode L, Eveillard M, Trichet V, Soussi T, Wuilleme S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traulle C, Guilhot F, Caillot D, Marit G, Mathiot C, Facon T, Attal M, Harousseau JL, Moreau P, Minvielle S & Avet-Loiseau H (2010) Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica, 95: 1973–1976  PDF LINK

Soussi T (2010) The history of p53. A perfect example of the drawbacks of scientific paradigms. EMBO Rep, 11: 822–826 PDFLINK


Carlsson J, Soussi T & Persson B (2009) Investigation and prediction of the severity of p53 mutants using parameters from structural calculations. FEBS J, 276: 4142–4155  PDFLINK

Soussi T & Hjortsberg L (2009) When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy? Trends Mol Med, 15: 1–4  PDFLINK


Berglind H, Pawitan Y, Kato S, Ishioka C & Soussi T (2008) Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther, 7: 699–708  PDF LINK

Soussi Zander C & Soussi T (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med, 358: 1635; author reply 1636  PDFLINK

Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A, Vicencio JM, Soussi T & Kroemer G (2008) Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle, 7: 3056–3061 PDFLINK


Soussi T (2007) p53 alterations in human cancer: more questions than answers. Oncogene, 26: 2145–2156  PDFLINK

Soussi T & Wiman KG (2007) Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell, 12: 303–312  PDFLINK

Ren ZP, Olofsson T, Qu M, Hesselager G, Soussi T, Kalimo H, Smits A & Nister M (2007) Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors. J Neuropathol Exp Neurol, 66: 944–954  PDFLINK


Go to top